David Fleischer, MD, discusses recent data for Viaskin Peanut patch

New insights from the pivotal phase 3 VITESSE trial continue to shape the clinical conversation around epicutaneous immunotherapy for peanut allergy, particularly in younger children. In an interview following the release of positive top-line results for DBV Technologies’ Viaskin Peanut patch, David Fleischer, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE study, outlined why the findings may be especially meaningful for pediatric allergy care.